{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:04:00Z","timestamp":1781654640220,"version":"3.54.5"},"reference-count":65,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Systemic sclerosis (SSc) is a heterogeneous disease with a variable disease course. Interstitial lung disease (ILD) is one of the leading causes of morbidity and mortality in patients with SSc. The present review highlights recent advances in the classification, diagnosis, and early detection of SSc-associated ILD (SSc-ILD).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Risk stratification through measurement of disease extent on high-resolution computed tomography (HRCT) of the chest, longitudinal declines in pulmonary function tests (PFTs), and mortality prediction models have formed the basis for classifying clinically significant ILD. HRCT may be preferred over PFTs for screening, as PFTs lack sensitivity and have a high false-negative rate. Novel imaging modalities and biomarkers hold promise as adjunct methods for assessing the presence and severity of SSc-ILD, and predicting risk for progressive disease. Further validation is required prior to their use in clinical settings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Classification of SSc-ILD has shifted to a personalized approach that considers an individual patient's probability of progressive disease through identification of risk factors, measurement of disease extent on HRCT, longitudinal declines in PFTs, and mortality prediction models. There remains an unmet need to develop screening guidelines for SSc-ILD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000660","type":"journal-article","created":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T11:33:02Z","timestamp":1565782382000},"page":"553-560","source":"Crossref","is-referenced-by-count":26,"title":["Detection and classification of systemic sclerosis-related interstitial lung disease: a review"],"prefix":"10.1097","volume":"31","author":[{"given":"Daniel J.","family":"DeMizio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elana J.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230828","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"R2-20230828","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5301\/jsrd.5000249","article-title":"Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities","volume":"2","author":"Varga","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"R3-20230828","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R5-20230828","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1007\/s10067-018-4291-z","article-title":"Survival rate, causes of death, and risk factors in systemic sclerosis: a large cohort study","volume":"37","author":"Li","year":"2018","journal-title":"Clin Rheumatol"},{"key":"R6-20230828","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R8-20230828","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis: pulmonary complications and survival in SSc","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R9-20230828","doi-asserted-by":"crossref","first-page":"e0163894","DOI":"10.1371\/journal.pone.0163894","article-title":"Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR Study. Assassi S, editor","volume":"11","author":"Jaeger","year":"2016","journal-title":"PLoS ONE"},{"key":"R10-20230828","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1002\/art.34482","article-title":"A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis","volume":"64","author":"Steen","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R11-20230828","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"R12-20230828","first-page":"NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis\u2013associated interstitial lung disease","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1378\/chest.08-0053","article-title":"Clinically significant interstitial lung disease in limited scleroderma","volume":"134","author":"Fischer","year":"2008","journal-title":"Chest"},{"key":"R15-20230828","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1378\/chest.07-2444","article-title":"High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease","volume":"134","author":"Goldin","year":"2008","journal-title":"Chest"},{"key":"R16-20230828","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1164\/rccm.2106012","article-title":"Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome","volume":"165","author":"Bouros","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"R17-20230828","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11926-014-0425-8","article-title":"Personalized medicine in systemic sclerosis: facts and promises","volume":"16","author":"Dobrota","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"R18-20230828","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"R19-20230828","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/rheumatology\/kes289","article-title":"Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease","volume":"52","author":"Moore","year":"2013","journal-title":"Rheumatology"},{"key":"R20-20230828","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.semarthrit.2017.03.019","article-title":"Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis","volume":"47","author":"Hax","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"(4 Suppl 91)","key":"R21-20230828","first-page":"S111","article-title":"Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease","volume":"33","author":"Moore","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"R22-20230828","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/rheumatology\/kev016","article-title":"Changes in forced vital capacity over time in systemic sclerosis: application of group-based trajectory modelling","volume":"54","author":"Man","year":"2015","journal-title":"Rheumatology"},{"key":"R23-20230828","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/art.40130","article-title":"Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis: pulmonary function trends in SSc-associated ILD","volume":"69","author":"Goh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R24-20230828","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/art.39166","article-title":"Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis: serial lung analyses in SSc","volume":"67","author":"Hoffmann-Vold","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R25-20230828","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.3899\/jrheum.141182","article-title":"Connective tissue disease-associated interstitial lung diseases (CTD-ILD)---report from OMERACT CTD-ILD Working Group","volume":"42","author":"Khanna","year":"2015","journal-title":"J Rheumatol"},{"key":"R26-20230828","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/annrheumdis-2018-213708","article-title":"Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts","volume":"78","author":"Volkmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R27-20230828","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/acr.21968","article-title":"Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?","volume":"65","author":"Liu","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R28-20230828","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1378\/chest.13-2626","article-title":"Predictors of mortality and progression in scleroderma-associated interstitial lung disease","volume":"146","author":"Winstone","year":"2014","journal-title":"Chest"},{"key":"R29-20230828","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1038\/s41598-018-23073-3","article-title":"Comparison of CPI and GAP models in patients with idiopathic pulmonary fibrosis: a nationwide cohort study","volume":"8","author":"Lee","year":"2018","journal-title":"Sci Rep"},{"key":"R30-20230828","doi-asserted-by":"crossref","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","article-title":"A multidimensional index and staging system for idiopathic pulmonary fibrosis","volume":"156","author":"Ley","year":"2012","journal-title":"Ann Intern Med"},{"key":"R31-20230828","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1164\/rccm.2111053","article-title":"Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography","volume":"167","author":"Wells","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"R32-20230828","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1136\/annrheumdis-2018-213201","article-title":"Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model","volume":"77","author":"Wu","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R33-20230828","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.chest.2017.06.009","article-title":"Mortality risk prediction in scleroderma-related interstitial lung disease: the SADL model","volume":"152","author":"Morisset","year":"2017","journal-title":"Chest"},{"key":"R34-20230828","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5114\/reum.2018.77977","article-title":"Interstitial lung disease in systemic sclerosis: challenges in early diagnosis and management","volume":"56","author":"Chowaniec","year":"2018","journal-title":"Reumatologia"},{"key":"R35-20230828","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/art.40769","article-title":"Proceedings of the American College of Rheumatology\/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: a multidisciplinary approach to address challenges and opportunities","volume":"71","author":"Fischer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R36-20230828","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1002\/art.39405","article-title":"Brief Report: Pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease: pulmonary function tests to screen for SSc-related ILD","volume":"67","author":"Suliman","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R37-20230828","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3899\/jrheum.171362","article-title":"Performance of forced vital capacity and lung diffusion cutpoints for associated radiographic interstitial lung disease in systemic sclerosis","volume":"45","author":"Showalter","year":"2018","journal-title":"J Rheumatol"},{"key":"R38-20230828","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"R39-20230828","first-page":"1789","article-title":"High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis","volume":"33","author":"Launay","year":"2006","journal-title":"J Rheumatol"},{"key":"R40-20230828","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1164\/rccm.201703-0555OC","article-title":"High-attenuation areas on chest computed tomography and clinical respiratory outcomes in community-dwelling adults","volume":"196","author":"Podolanczuk","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"R41-20230828","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1183\/13993003.00129-2016","article-title":"High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study","volume":"48","author":"Podolanczuk","year":"2016","journal-title":"Eur Respir J"},{"key":"R42-20230828","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/art.40441","article-title":"Screening high-resolution computed tomography of the chest to detect interstitial lung disease in systemic sclerosis: a global survey of rheumatologists","volume":"70","author":"Bernstein","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"(Suppl 114(5))","key":"R43-20230828","first-page":"165","article-title":"The use of ultrasound for assessing interstitial lung involvement in connective tissue diseases","volume":"36","author":"Ferro","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"R44-20230828","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13075-019-1888-9","article-title":"A simplified lung ultrasound for the diagnosis of interstitial lung disease in connective tissue disease: a meta-analysis","volume":"21","author":"Xie","year":"2019","journal-title":"Arthritis Res Therapy"},{"key":"R45-20230828","article-title":"Lung ultrasound as a screening method for interstitial lung disease in patients with systemic sclerosis","volume":"1","author":"Hassan","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"R46-20230828","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/annrheumdis-2011-201072","article-title":"Lung ultrasound for the screening of interstitial lung disease in very early systemic sclerosis","volume":"72","author":"Milanese","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R47-20230828","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11739-015-1329-y","article-title":"Lung ultrasound in systemic sclerosis: correlation with high-resolution computed tomography, pulmonary function tests and clinical variables of disease","volume":"11","author":"Gigante","year":"2016","journal-title":"Intern Emerg Med"},{"key":"R48-20230828","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1109\/TBME.2018.2872907","article-title":"Lung ultrasound surface wave elastography for assessing interstitial lung disease","volume":"66","author":"Zhang","year":"2019","journal-title":"IEEE Trans Biomed Eng"},{"key":"R49-20230828","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11926-019-0826-9","article-title":"Novel imaging approaches in systemic sclerosis-associated interstitial lung disease","volume":"21","author":"Montesi","year":"2019","journal-title":"Curr Rheumatol Rep"},{"issue":"(Suppl 2)","key":"R50-20230828","first-page":"749","article-title":"FRI0439 The promising role of lung MRI in detecting systemic sclerosis (SSc)-related interstitial lung disease (ILD)","volume":"77","author":"Gargani","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R51-20230828","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/annrheumdis-2018-214322","article-title":"Visualisation of interstitial lung disease by molecular imaging of integrin \u03b1v\u03b23 and somatostatin receptor 2","volume":"78","author":"Schniering","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R52-20230828","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/14737159.2017.1356722","article-title":"An update on biomarker discovery and use in systemic sclerosis","volume":"17","author":"Matsushita","year":"2017","journal-title":"Expert Rev Mol Diagn"},{"key":"R53-20230828","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.clim.2017.09.015","article-title":"Interstitial lung disease in the connective tissue diseases; a paradigm shift in diagnosis and treatment","volume":"186","author":"Dellaripa","year":"2018","journal-title":"Clin Immunol"},{"key":"R54-20230828","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/art.40171","article-title":"CCL2 in the circulation predicts long-term progression of interstitial lung disease in patients with early systemic sclerosis: data from two independent cohorts: CCL2 predicts SSc-related ILD progression","volume":"69","author":"Wu","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R55-20230828","doi-asserted-by":"crossref","first-page":"e0206545","DOI":"10.1371\/journal.pone.0206545","article-title":"Augmented concentrations of CX3CL1 are associated with interstitial lung disease in systemic sclerosis. Kuwana M, editor","volume":"13","author":"Hoffmann-Vold","year":"2018","journal-title":"PLOS ONE"},{"key":"R56-20230828","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3899\/jrheum.170518","article-title":"KL-6 But Not CCL-18 is a predictor of early progression in systemic sclerosis-related interstitial lung disease","volume":"45","author":"Salazar","year":"2018","journal-title":"J Rheumatol"},{"key":"R57-20230828","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13075-018-1545-8","article-title":"Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis","volume":"20","author":"Weigold","year":"2018","journal-title":"Arthritis Res Therapy"},{"key":"R58-20230828","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/art.40815","article-title":"Performance of candidate serum biomarkers for systemic sclerosis\u2013associated interstitial lung disease","volume":"71","author":"Elhai","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R59-20230828","first-page":"1112","article-title":"Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis","volume":"31","author":"Yanaba","year":"2004","journal-title":"J Rheumatol"},{"key":"R60-20230828","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3899\/jrheum.080633","article-title":"Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma","volume":"36","author":"Hant","year":"2009","journal-title":"J Rheumatol"},{"key":"R61-20230828","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00296-018-3987-3","article-title":"Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease","volume":"38","author":"Benyamine","year":"2018","journal-title":"Rheumatol Int"},{"key":"R62-20230828","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13075-019-1835-9","article-title":"Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease","volume":"21","author":"Lee","year":"2019","journal-title":"Arthritis Res Therapy"},{"key":"R63-20230828","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1183\/09031936.00004711","article-title":"Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis","volume":"38","author":"Tiev","year":"2011","journal-title":"Eur Respir J"},{"key":"R64-20230828","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1183\/09031936.00131713","article-title":"Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis","volume":"43","author":"Schupp","year":"2014","journal-title":"Eur Respir J"},{"key":"R65-20230828","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.chest.2016.03.004","article-title":"High level of chemokine CCL18 is associated with pulmonary function deterioration, lung fibrosis progression, and reduced survival in systemic sclerosis","volume":"150","author":"Hoffmann-Vold","year":"2016","journal-title":"Chest"},{"key":"R66-20230828","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/1756-185X.13452","article-title":"Serum levels of Krebs von den Lungen-6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis-associated interstitial lung disease from a Chinese cohort","volume":"22","author":"Cao","year":"2019","journal-title":"Int J Rheum Dis"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000660","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T06:00:31Z","timestamp":1693202431000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000660","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}